CorMedix Inc. (NASDAQ: CRMD) shares surged 5.20% in pre-market trading on Tuesday following the release of its impressive first-quarter 2025 financial results and a positive business update. The specialty pharmaceutical company, focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases, delivered strong performance that exceeded analysts' expectations.

CorMedix reported quarterly earnings of $0.30 per share, significantly beating the analyst consensus estimate of $0.24 by 25%. This represents a substantial turnaround from the same period last year when the company posted a loss of $0.25 per share. Revenue for the quarter came in at $39.08 million, surpassing the analyst consensus estimate of $36.00 million by 8.55%.

The company's strong financial position was further underscored by its healthy cash and investments balance of $77.5 million. Looking ahead, CorMedix expressed optimism about its near-term prospects, stating that it expects to reach the high end of its first-half 2025 sales guidance range of $62 million to $70 million. This positive outlook, combined with the better-than-expected quarterly results, likely contributed to the significant pre-market stock price increase as investors responded favorably to the company's performance and future potential.